The range of dietary supplements contains a formulation of macular pigments including mesozeaxanthin, lutein and zeaxanthin, which may be provide benefit to some patients with eye conditions, including dry age-related macular degeneration (AMD).
The acquisition adds Macushield to the Alliance portfolio, which covers a number of therapeutic areas including dermatology and nutrition.
Commenting on the acquisition, chief executive of Alliance Pharma, John Dawson, said: “We are delighted to start the year with this important acquisition of MacuShield. It’s a great addition to our range of products and it is the UK’s most recommended eye supplement by opticians. An important aspect of our growth strategy is to continue to build strong relationships and educate the eye care professionals about the supplements.”